CA-CLICKHOUSE
25.6.2024 17:46:36 CEST | Business Wire | Press release
ClickHouse Inc, a leader in real-time analytics, announces the expansion of ClickHouse Cloud to Microsoft Azure, providing users with even more options for deploying and managing their analytics workloads. With this expansion, ClickHouse Cloud is now available on three major cloud service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625765046/en/
ClickHouse Cloud is now generally available on Microsoft Azure (Graphic: Business Wire)
As organizations increasingly adopt real-time analytics databases in their interactive, data-driven customer-facing applications, as well as in their internal data warehousing and data science workflows, ClickHouse Cloud availability on Azure offers customers greater flexibility and choice. Availability of ClickHouse Cloud in Azure Marketplace allows users to use existing Azure investments and take advantage of integrations with Azure-specific services including Microsoft Power BI and Azure Event Hubs.
“Companies of all sizes trust ClickHouse to gain valuable insights from their data, across a wide variety of use cases,” says Aaron Katz, Co-founder and CEO of ClickHouse, Inc. “This announcement reiterates our vision to bring the best real-time data warehouse to our users regardless of which cloud provider they use.”
“With ClickHouse Cloud generally available on Microsoft Azure, enterprise and digital-native companies alike can take advantage of its breadth of use cases on one of the most open and flexible cloud platforms,” said Erin Chapple, corporate vice president, Azure Core Products and Design at Microsoft. “Mutual customers and partners can now benefit from real-time analytics and business intelligence solutions to gain valuable insights from their data in new ways.”
Public Beta for ClickHouse Cloud on Azure was announced at Microsoft Build in May 2024 and is seeing strong adoption across organizations looking to build real-time analytical applications on top of Azure.
"We are thrilled about the launch of ClickHouse Cloud on Microsoft Azure," said Julian LaNeve, Chief Technology Officer at Astronomer. "Our data platform handles massive volumes of real-time events, and ClickHouse has been instrumental in delivering lightning-fast analytics. With ClickHouse Cloud on Azure, we can deploy and scale effortlessly on Azure's reliable, secure, and scalable infrastructure."
“At BaxEnergy, our mission is to make renewable energy easier, more efficient, affordable, and secure," said Marco Cecconi, Head of R&D of BaxEnergy. “ClickHouse Cloud on Microsoft Azure supports us in conducting advanced analysis on large volumes of data from various renewable energy sources. By generating actionable insights, creating detailed reports, and developing custom dashboards, we empower our customers to achieve better performance and scale their operations effectively. We have been pleasantly surprised by the remarkable speed and flexibility of ClickHouse, and their team has provided us with exceptional dedicated support.”
Some additional benefits of using ClickHouse Cloud on Azure include:
Simplicity. With ClickHouse Cloud, you create your service with a single click. You don't have to worry about the operational complexity of server configurations and cluster topology, shards and replicas, managing backups and restores, durability and fault tolerance, monitoring, or alerts. It just works.
Speed and Scale. ClickHouse Cloud is designed to handle real-time analytics on top of petabyte-scale datasets. There is no need for manual sharding or data movement, as it scales automatically. Our multi-layer cache and other cloud-native performance optimizations ensure impressive query performance for a wide variety of workloads.
Security and Reliability. ClickHouse Cloud has security best practices built in by default. It is configured with network isolation and traffic encryption. ClickHouse builds are additionally hardened, tested, and validated for ClickHouse Cloud. The service is automatically replicated across multiple availability zones for high availability.
Efficiency. ClickHouse Cloud adapts itself to the changing nature of your workloads, scaling up and down as needed. ClickHouse Cloud also takes advantage of shared object storage as its primary storage, while separating compute resources. This dramatically increases flexibility and resource efficiency, delivering industry's best price/performance ratio.
Ecosystem. Easy-to-use integrations allow users to seamlessly ingest data and interface with internal and external systems. A curated set of core and partner integrations vetted to work seamlessly with ClickHouse Cloud are provided in addition to hundreds of community-built integrations. Within the Azure ecosystem, ClickHouse Cloud features turnkey integrations with Azure Event Hubs, Power BI, and Azure Blob Storage.
ClickHouse Cloud offers a 30-day trial that includes $300 free usage credits. To get started, sign up here or subscribe from Azure Marketplace.
About ClickHouse
ClickHouse is a fast, open-source columnar database management system that allows for real-time data processing and analytics. Engineered for high performance, ClickHouse Cloud delivers exceptional query speed, making it an ideal solution for handling large volumes of data. Trusted by leading companies like Lyft, Deutsche Bank and LangChain, ClickHouse Cloud enables businesses to gain critical insights and drive decision-making with its scalable, efficient, and robust data infrastructure. For more information, visit clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625765046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom